ERBIN:: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor

被引:256
|
作者
Borg, JP
Marchetto, S
Le Bivic, A
Ollendorff, V
Jaulin-Bastard, F
Saito, H
Fournier, E
Adélaïde, J
Margolis, B
Birnbaum, D
机构
[1] INSERM, U119, F-13009 Marseille, France
[2] Fac Sci Luminy, IBDM, F-13288 Marseille 09, France
[3] Inst J Paoli I Calmettes, F-13009 Marseille, France
[4] Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA
关键词
D O I
10.1038/35017038
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The ERBB receptors have a crucial role in morphogenesis and oncogenesis. We have identified a new PDZ protein we named ERBIN (ERBB2 interacting protein) that acts as an adaptor for the receptor ERBB2/HER2 in epithelia. ERBIN contains 16 leucine-rich repeats (LRRs) in its amino terminus and a PDZ (PSD-95/DLG/ZO-1) domain at its carboxy terminus, and belongs to a new PDZ protein family. The PDZ domain directly and specifically interacts with ERBB2/ HER2. ERBIN and ERBB2/HER2 colocalize to the lateral membrane of human intestinal epithelial cells. The ERBIN-binding site in ERBB2/HER2 has a critical role in restricting this receptor to the basolateral membrane of epithelial cells, as mutation of the ERBIN-binding site leads to the mislocalization of the receptor in these cells. We suggest that ERBIN acts in the localization and signalling of ERBB2/HER2 in epithelia.
引用
收藏
页码:407 / 414
页数:8
相关论文
共 50 条
  • [41] HER2/ERBB2 Testing in Breast Carcinoma by Next Generation Sequencing
    Wong, Adele
    Bhan, Atul
    Lennerz, Jochen K.
    Brachtel, Elena
    LABORATORY INVESTIGATION, 2017, 97 : 522A - 522A
  • [42] Concomitant mutation and amplification of the ERBB2 (HER2) gene in human tumors
    Grob, Tobias
    Sandmann, Mareike
    Quaas, Alexander
    Marx, Andreas
    Sauter, Guido
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] COMPLETE - Study the ErbB2 (HER2) - positive Breast cancer.
    Arnheim, Katharina
    Aktas, Bahriye
    ONKOLOGIE, 2010, 33 (04):
  • [44] When Tumor Suppressor TGFβ Meets the HER2 (ERBB2) Oncogene
    Amy Chow
    Carlos L. Arteaga
    Shizhen Emily Wang
    Journal of Mammary Gland Biology and Neoplasia, 2011, 16 : 81 - 88
  • [45] The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer
    Lippa, Blaise
    Kauffman, Goss S.
    Arcari, Joel
    Kwan, Tricia
    Chen, Jinshan
    Hungerford, William
    Bhattacharya, Samit
    Zhao, Xumiao
    Williams, Courtney
    Xiao, Jun
    Pustilnik, Leslie
    Su, Chunyan
    Moyer, James D.
    Ma, Ling
    Campbell, Mary
    Steyn, Stefanus
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (11) : 3081 - 3086
  • [46] erbB1/HER1和erbB2/HER2在肺癌的表达
    邓在春
    俞文英
    胡国平
    郑如恒
    张敦华
    谭云山
    徐永华
    江万里
    现代实用医学, 2001, (11) : 539 - 541
  • [47] ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer
    Stern, David F.
    JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2008, 13 (02) : 215 - 223
  • [48] HER2/ErbB2 Receptor Signaling in Rat and Human Prolactinoma Cells: Strategy for Targeted Prolactinoma Therapy
    Fukuoka, Hidenori
    Cooper, Odelia
    Mizutani, Jun
    Tong, Yunguang
    Ren, Song-Guang
    Bannykh, Serguei
    Melmed, Shlomo
    MOLECULAR ENDOCRINOLOGY, 2011, 25 (01) : 92 - 103
  • [49] HER2/neu (erbB2) kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGF receptors
    Wang, Shizhen Emily
    Narasanna, Archana
    Perez-Torres, Marianela
    Xiang, Bin
    Dugger, Teresa C.
    Wu, Frederick Y.
    Yang, Seungchan
    Gazdar, Adi F.
    Muthuswamy, Senthil K.
    Arteaga, Carlos L.
    CANCER RESEARCH, 2006, 66 (08)
  • [50] Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signaling
    J-H Zhu
    R Chen
    W Yi
    G T Cantin
    C Fearns
    Y Yang
    J R Yates
    J-D Lee
    Oncogene, 2008, 27 : 2525 - 2531